GALVANIZE
10.3.2020 14:02:15 CET | Business Wire | Press release
Galvanize , the leader in SaaS governance, risk, and compliance (GRC) software, is pleased to announce that it has been named a Leader in The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020.
Galvanize received the top scores possible in the risk and control management, document management, audit management, and IT risk management criteria. In addition, the company was among the top ranked in the criteria of advanced predictive analytics, which is defined as “superior capabilities relative to others in the evaluation, including AI and ML capability to support advanced modelling in Python and R, advanced anomaly detection, and continuous auditing.”
“We’re extremely proud to be named as a Leader in Forrester’s rigorous evaluation system,” said Dan Zitting, chief product & strategy officer, Galvanize. “We believe this accomplishment is a testament to the hard work of marrying our GRC platforms to create an end-to-end system that sets the industry standard for stronger IT security, risk management, compliance, and assurance.”
The report notes the company’s successful integration of ACL and Rsam to create a combined industry catalyst. According to the report, the HighBond platform, which has achieved FedRAMP Moderate authorization, “combines Rsam’s aptitude for collecting and operationalizing data with ACL’s powerful analytics and robotic process automation, enabling GRC pros to capitalize on digital transformation”. The report explains: “Notwithstanding the sophistication, customers enjoy managing the platform themselves and appreciate Client Partners, the vendor’s unique take on customer success that combines guidance, best practices, and access to other customers to help solve similar problems.”
“We’re witnessing a shift among the world’s most influential businesses, as they demand value from organizations that stretch beyond financial profit,” said Laurie Schultz, president & CEO, Galvanize. “Being recognized as a Leader by Forrester is extremely impactful, as it corroborates our unique vision to create a comprehensive GRC offering worthy of tomorrow’s workforce, as well as bringing us closer to our goal of consolidating the GRC industry, and being the operating system for conscious organizations.”
The Forrester Wave™ is one of the industry’s most complete and detailed analyses, using a transparent methodology composed of vendor surveys, product demos, and customer reference calls to compare top players in the market. This latest recognition builds on a long history of industry recognition among leading analyst firms for Galvanize. The company was named a Leader in Gartner Magic Quadrant for IT Vendor Risk Management Tools in December 2019 and a Leader in Gartner Magic Quadrant for IT Risk Management in July 2019.
A full, complimentary version of the report, The Forrester Wave™: Governance, Risk, and Compliance Software, Q1 2020 is available for download from Galvanize at: https://info.wegalvanize.com/forrester-wave-grc-platforms-2020-report.html
To learn more about Galvanize and its comprehensive GRC platform, visit: wegalvanize.com .
About Galvanize:
Galvanize builds award-winning, cloud-based security, risk management, compliance, and audit software to drive change in some of the world’s largest organizations. We’re on a mission to unite and strengthen individuals and entire organizations through the integrated HighBond software platform. With more than 6,300 customer organizations in 130 countries, Galvanize is connecting teams in many of the Fortune 1,000 and S&P 500 companies, and hundreds of government organizations, banks, manufacturers, and healthcare organizations. Whether these professionals are managing threats, assessing risk, measuring controls, monitoring compliance, or expanding assurance coverage, HighBond automates manual tasks, blends organization-wide data, and broadcasts it in easy-to-share dashboards and reports. But we don’t just make technology—we provide tools that inspire individuals to achieve great things and do heroic work in the process.
Supporting Resources:
Website: www.wegalvanize.com
Twitter: https://twitter.com/wegalvanize
LinkedIn: https://linkedin.com/company/wegalvanize
©2020 ACL Services Ltd. ACL, Galvanize, the Galvanize logo, HighBond, and the HighBond logo are trademarks or registered trademarks of ACL Services Ltd. dba Galvanize. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200310005234/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom